• FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19
• FDA Roundup: January 21, 2022
• FDA Roundup: January 18, 2022
• FDA Releases CDRH Health of Women Strategic Plan to Better Inform Medical Device Research and Regulation for All Women
• FDA Roundup: January 14, 2022

• Graduation rates dip across US as pandemic stalls progress
• Evidence for a semisolid phase state of aerosols and droplets relevant to the airborne and surface survival of pathogens
• Two-thirds of anti-vax propaganda online created by just 12 influencers, research finds
• Daily Discussion Thread | January 24, 2022
• Health Ministry: 4th dose triples protection from serious illness for over-60s

• Safety of COVID-19 Vaccine
• Small and Large Gatherings
• Omicron Variant: What You Need to Know
• COVID-19 Testing: What You Need to Know
• What You Need to Know About Variants ' CDC

• An investigation for the interaction of gamma oryzanol with the Mpro of SARS-CoV-2 to combat COVID-19: DFT, molecular docking, ADME and molecular dynamics simulations
• The COVID-19-diabetes mellitus molecular tetrahedron
• Development and evaluation of peptidomimetic compounds against SARS-CoV-2 spike protein: an in silico and in vitro study
• COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
• Favipiravir in Kidney Transplant Recipients With COVID-19: A Romanian Case Series

• Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
• Randomised Evaluation of COVID-19 Therapy
• Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

• Shorter serial intervals in SARS-CoV-2 cases with Omicron variant compared to Delta variant in the Netherlands, 13 – 19 December 2021
• Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
• Severe outcomes in residents of Long Term Care Facilities following infection with SARS-CoV-2 Omicron variant (VIVALDI study)
• Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis
• Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients

• COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
• GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
• Hydroxychloroquine in Treatment of Asymptomatic and Mildly Symptomatic COVID-19: A Multi-Centre Cohort Study
• Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists
• Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar

• Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab
• Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
• Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19
• Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
• ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

• Em Manutenção

• Pancreas artificiale per diabete di tipo 2: l’approccio simbolico
• I numeri di COVID-19 tra modelli, previsioni e comunicazione
• Dopo il cuore, riuscito anche il trapianto di rene da maiale
• Covid, la parola agli psicologi
• Studio a lungo termine dimostra efficacia e sicurezza della terapia genica per la leucodistrofia metacromatica